Heart failure & cardiomyopathies
Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort
Authors' conclusion
Mavacamten treatment showed clinically important and durable improvements in LVOT gradients, NT-proBNP levels, and NYHA functional class, consistent with EXPLORER-HCM. Mavacamten treatment was well tolerated over a median 62-week follow-up.
Study context
- Population
- Patients with symptomatic obstructive hypertrophic cardiomyopathy who completed EXPLORER-HCM217 remained on treatment
- Participants
- 231 patients
- Outcome
- Change from baseline at 48 weeks (single-group, interim results)
- Follow-up
- 48 weeks
Methodological detailsinterim analysis of the EXPLORER-LTE cohort of MAVA-LTE, long-term extension, single-group
- Interim analysis of the EXPLORER-LTE cohort of MAVA-LTE
- Long-term extension
- Single-group
Main finding
As reported in the abstract
Left ventricular outflow tract (LVOT) gradient, resting: mean change ± SD from baseline (mm Hg)
−35.6 ± 32.6 mm Hg
LVOT gradient, Valsalva: mean change ± SD from baseline (mm Hg)
−45.3 ± 35.9 mm Hg
NT-proBNP: median change (Q1-Q3 −1,104 to −179 ng/L)
−480 ng/L
NYHA class improved by ≥1 class
67.5%
Observational data: associations, not effects.
Further findings
LVOT gradients and NT-proBNP · 84 weeks
- Reductions sustained through 84 weeks in patients who reached this timepoint
Safety
Adverse events over 315 patient-years of exposure
- Patients with AE of cardiac failure
- 8
- Patients with AE of AF
- 21
- AF with no prior history of AF
- 11
- Transient site-read LVEF <50% with temporary treatment interruption; all recovered
- Twelve patients (5.2%)
- Discontinued treatment due to treatment-emergent AEs
- Ten
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →